|Table of Contents|

Advances in the treatment of intracranial hypertension caused by malignant tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 20
Page:
3983-3986
Research Field:
Publishing date:

Info

Title:
Advances in the treatment of intracranial hypertension caused by malignant tumors
Author(s):
GUO Xujin1; LI Zhaoxing2; FAN Huanfang1; XU Yapei3; MA Pan1; WU Haina1; WANG Xiao1
1The Second Department of Oncology,the First Affiliated Hospital of Hebei University of Chinese Medicine,Hebei Shijiazhuang 050011,China;2The Third Department of Surgery,Hebei Tumor Hospital,Hebei Shijiazhuang 050011,China；3Digestive Endoscopy Center,the First Affiliated Hospital of Hebei University of Chinese Medicine，Hebei Shijiazhuang 050011,China.
Keywords:
intracranial hypertension; tumor; treatment; review
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2024.20.031
Abstract:
Intracranial hypertension is a common clinical disease.Patients often have headache,vomiting,papilledema of the optic nerve,consciousness disorders and other clinical manifestations.The disease belongs to the nervous system acute critical illness.Severe cases can cause cerebral hernia,resulting in death of the patient.Tumor,trauma,stroke,encephalitis,hepatic encephalopathy,hypoxia and other reasons can lead to the occurrence of the disease.Tumor is one of the common causes of this disease,and there are many related cases.However,there is no review on the treatment of intracranial hypertension caused by tumor.In this paper,by combining the traditional treatment of the disease and the new treatment methods in recent years,the treatment methods of tumor induced intracranial hypertension were systematically reviewed,in order to provide certain guidance for the clinical treatment of the disease.

References:

［1］ CANAC N,JALALEDDINI K,THORPE SG,et al.Review:pathophysiology of intracranial hypertension and noninvasive intracranial pressure monitoring［J］.Fluids Barriers CNS,2020,17(1):40.
［2］ RASULO FA,CALZA S,ROBBA C,et al.Transcranial Doppler as a screening test to exclude intracranial hypertension in brain-injured patients:the IMPRESSIT-2 prospective multicenter international study［J］.Crit Care,2022,26(1):110.
［3］ 姚沛,段华新.脑转移瘤免疫治疗临床进展［J］.中华肿瘤防治杂志,2022,29(15):1087-1093. YAO P,DUAN HX.Clinical progress of immunotherapy for brain metastases［J］.Chinese Journal of Cancer Prevention and Treatment,2022,29(15):1087-1093.
［4］ 钱援芳,万如.1例妊娠末期合并松果体细胞瘤术后颅内高压及精神分裂症的护理［J］.中华护理杂志,2018,53(01):120-122. QIAN YF,WAN R.Nursing care of one full-term pregnant patient with schizophrenia and postoperative intracranial hypertension after pineal tumor surgery［J］.Chinese Journal of Nursing,2018,53(01):120-122.
［5］ THAKUR K,KAUR H,DHANDAPANI M,et al.Systematic review exploring the effect of therapeutic hypothermia on patients with intracranial hypertension［J］.Surg Neurol Int,2022,3(13):237.
［6］ WANG P,GAO BB,WANG M,et al.Challenges in the nursing care of intracranial carbapenem-resistant Escherichia coli infection after severe traumatic brain injury:a case report［J］.Ann Palliat Med,2020,9(4):2381-2385.
［7］ SACCO TL,DAVIS JG.Management of intracranial pressure part Ⅱ:nonpharmacologic interventions［J］.Dimens Crit Care Nurs,2019,38(2):61-69.
［8］ SACCO TL,DELIBERT SA.Management of intracranial pressure part Ⅰ:Pharmacologic interventions［J］.Dimens Crit Care Nurs,2018,37(3):120-129.
［9］ GILBERT BW,DINGMAN JS,REEDER JA,et al.A teaspoon of sugar and a pinch of salt:Reviewing hyperosmolar therapy［J］.JAAPA,2022,35(3):43-47.
［10］ LAMPERTI M,LOBO FA,TUFEGDGIC B.Salted or sweet? Hypertonic saline or mannitol for treatment of intracranial hypertension［J］.Curr Opin Anaesthesiol,2022,35(5):555-561.
［11］ 中华医学会神经外科学分会,中国神经外科重症管理协作组,中国神经外科转化与循证医学协作组,等.高渗盐水治疗脑水肿及颅内高压的专家共识［J］.中华医学杂志,2022,102(17):1258-1266. Chinese Society of Neurosurgery,Chinese Neurosurgical Critical Care Management Collaboration Group,Chinese Collaborative Group of Translational Neurosurgery and Evidence-based Medicine,et al.Expert consensus on hypertonic saline treatment of cerebral edema and intracranial hypertension［J］.National Medical Journal of China,2022,102(17):1258-1266.
［12］ O' BRIEN SK,KOEHL JL,DEMERS LB,et al.Safety and tolerability of 23.4% hypertonic saline administered over 2 to 5 minutes for the treatment of cerebral herniation and intracranial pressure elevation［J］.Neurocrit Care,2023,38(2):312-319.
［13］ 黎明丽,宋薇,胡汉昆,等.甘油果糖注射液对比甘露醇注射液治疗脑水肿疗效和安全性的Meta分析［J］.中国药房,2014,25(44):4140-4143. LI ML,SONG W,HU HK,et al.Therapeutic efficacy and safety of glycerol and fructose injection vs mannitol injection in the treatment of cerebral edema:A meta-analysis［J］.China Pharmacy,2014,25(44):4140-4143.
［14］ LIU SH,SONG YY,ZHANG IY,et al.RAGE inhibitors as alternatives to dexamethasone for managing cerebral edema following brain tumor surgery［J］.Neurotherapeutics,2022,19(2):635-648.
［15］ EID PS,IBRAHIM DA,ZAYAN AH,et al.Comparative effects of furosemide and other diuretics in the treatment of heart failure:a systematic review and combined meta-analysis of randomized controlled trials［J］.Heart Fail Rev,2021,26(1):127-136.
［16］ SAWANT-POKAM PA,VAIL TY,MEYCALF CS,et al.Preventing neuronal edema increases network excitability after traumatic brain injury［J］.J Clin Invest,2020,130(11):6005-6020.
［17］ 张伟,王政.中国抗癌协会脑胶质瘤整合诊治指南（精简版）［J］.中国肿瘤临床,2022,49(16):811-818. ZHANG W,WANG Z.China Anti-Cancer Association guidelines for integrative diagnosis and treatment of glioma (abridged version)［J］.Chinese Journal of Clinical Oncology,2022,49(16):811-818.
［18］ GOLDBRUNNER R,STAVRINOU P,JENKINSON MD,et al.EANO guideline on the diagnosis and management of meningiomas［J］.Neuro Oncol,2021,23(11):1821-1834.
［19］ 李振兴,寿雪飞.中国垂体瘤卒中诊治专家共识［J］.临床神经外科杂志,2022,19(06):601-608. LI ZX,SHOU XF.Chinese experts' consensus on diagnosis and treatment of pituitary apoplexy［J］.Journal of Clinical Neurosurgery,2022,19(06):601-608.
［20］ SU YH,CHIANG CL,YANG HC,et al.Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis［J］.Acta Neurochir (Wien),2022,164(2):459-467.
［21］ HAWRYLUK GW,RUBINAO AW,TOTTEN AM,et al.Guidelines for the management of severe traumatic brain injury:2020 update of the decompressive craniectomy recommendations［J］.Neurosurgery,2020,87(3):427-434.
［22］ 张碧营,何泽来,吴双,等.甲磺酸奥希替尼治疗EGFR基因突变型非小细胞肺癌脑转移的疗效评价［J］.肿瘤,2021,41(02):110-120. ZHANG BY,HE ZL,WU S,et al.Prognostic analysis of osimertinib in the treatment of brain metastases from EGFR-mutant non-small-cell lung cancer［J］.Tumor,2021,41(02):110-120.
［23］ HUI C,QU V,WANG JY,et al.Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer［J］.J Neurooncol,2022,160(1):233-240.
［24］ 周清,陆舜,李勇,等.洛拉替尼特殊不良反应管理中国专家共识［J］.中国肺癌杂志,2022,25(08):555-566. ZHOU Q,LU S,LI Y,et al.Chinese expert consensus on management of special adverse effects associated with lorlatinib［J］.Chinese Journal of Lung Cancer,2022,25(08):555-566.
［25］ SOLOMON BJ,BAUER TM,OU SH,et al.Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase Ⅲ CROWN study［J］.J Clin Oncol,2022,40(31):3593-3602.
［26］ 汪雄,刁长冬,朱海霞,等.含替莫唑胺化疗方案不良反应发生情况及影响因素分析［J］.中国药学杂志,2021,56(17):1414-1419. WANG X,DIAO CD,ZHU HX,et al.Analysis of the occurrence and influencing factors of adverse reactions in the chemotherapy regimens containing temozolomide［J］.Chinese Pharmaceutical Journal,2021,56(17):1414-1419.
［27］ LIU PJ,REN RZ,YOU D,et al.Efficacy of synchronous stereotactic radiotherapy with temozolomide combined with whole brain radiotherapy in treating brain metastases originating from non-small cell lung cancer［J］.J BUON,2020,25(4):1771-1778.
［28］ 高靓,何蕊.国内贝伐珠单抗超说明书用药现状及分析［J］.药品评价,2022,19(17):1084-1088. GAO L,HE R.Current situation and analysis of bevacizumab over instruction in China［J］.Drug Evaluation,2022,19(17):1084-1088.
［29］ BAI XX,ZHANG Y,DING WL,et al.Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources［J］.Neurol Res,2021,43(12):955-960.
［30］ LI L,FENG M,XU P,et al.Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC［J］.Int J Neurosci,2023,133(3):334-341.
［31］ 李丹.脑转移瘤立体定向放射治疗疗效及预后影响因素的探讨［D］.长春：吉林大学,2020. LI D.Effect and prognostic factors of stereotactic radiotherapy for brain metastases［D］.Changchun:Jilin University,2020.
［32］ 王宏超.非小细胞肺癌脑转移全脑放疗的预后分析［D］.南昌：南昌大学,2022. WANG HC.Prognostic analysis of whole brain radiotherapy for non-small cell lung cancer with brain metastasis［D］.Nanchang:Nanchang University,2022.
［33］ 杨洋,周霞,杜向慧,等.全脑放疗在脑转移瘤治疗中的地位转变及争议［J］.临床肿瘤学杂志,2020,25(08):755-760. YANG Y,ZHOU X,DU XH,et al.Evolving role of whole brain radiotherapy in the management of brain metastatic tumors-controversies and update［J］.Chinese Clinical Oncology,2020,25(08):755-760.
［34］ CAO J,YANG YP,WANG G.Progress in radiotherapy for brain metastases［J］.Modern Oncology,2020,28(11):1985-1989.
［35］ DONG K,LIANG WH,ZHAO S,et al.EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases［J］.Transl Lung Cancer Res,2019,8(3):268-279.
［36］ ZHANG XM,CHEN YD,YAO J,et al.β-elemene combined with temozolomide in treatment of brain glioma［J］.Biochem Biophys Rep,2021,28(28):101144.

Memo

Memo:
河北省自然科学基金项目（编号：H2021423030）；河北省中医药管理局科研计划项目（编号：2024021,2024018，2020054）；河北省2023年政府资助临床医学优秀人才培养项目（编号：ZF2023161）；河北省2024年政府资助临床医学优秀人才培养项目（编号：ZF2024166）
Last Update: 1900-01-01